Pharmacopeia
Methylene blue
Core pharmacology
- Class Group
Thiazine dye; oxidation-reduction agent and methaemoglobinaemia antidote.
- Main Action
Promotes reduction of methaemoglobin (Fe3+) to functional haemoglobin (Fe2+); in vasoplegia, inhibits nitric-oxide/cGMP-mediated vasodilatation (off-label use).
- Mechanism of action
NADPH-dependent reduction converts methylene blue to leucomethylene blue, which donates reducing equivalents to methaemoglobin. In vasoplegia, inhibitory effects on nitric oxide synthase/soluble guanylate cyclase can decrease cGMP signalling.
- Indications Uses
Treatment of acquired methaemoglobinaemia; a rescue therapy sometimes considered for refractory vasoplegia, which is a separate off-label indication with less certain outcome evidence.
- Route And Dose
Intravenous for clinically significant acquired methaemoglobinaemia; follow locally approved product information and toxicology advice for dose, repeat dosing and preparation. Do not extrapolate a methaemoglobinaemia regimen to vasoplegia.
- Metabolism
Reduced in tissues to leucomethylene blue; redox cycling mediates methaemoglobin reduction.
- Adverse Effects Toxicity
Potentially severe serotonin syndrome with serotonergic medicines and some opioids due to MAO-inhibiting activity; haemolysis and reduced effectiveness in G6PD deficiency; paradoxical methaemoglobinaemia with excessive doses; blue-green discolouration and interference with pulse oximetry.
- Special Points
US methylene blue injection labelling contraindicates use in G6PD deficiency and contains a boxed serotonin-syndrome warning. In acquired methaemoglobinaemia, monitor clinical response and co-oximetry rather than relying on pulse oximetry alone. Vasoplegic-shock use remains off-label and should not be presented as equivalent to the established antidote indication.
Source references
These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.